This study investigated the outcomes of perioperative multidisciplinary nursing collaboration for patients who underwent laparoscopic radical prostatectomy.
Innoblative Designs, Inc. (Innoblative), a private medical device company addressing clinical unmet needs for patients with breast cancer, announced today that it has received Category III Current ...
In the world of surgical robots, there’s a new kid in town, and Atrium Health Wake Forest Medical Center is one of the first ...
A large national study in Denmark following nearly 1,900 patients over almost a decade found that a minimally invasive procedure ...
When South Korean doctors launched a nationwide thyroid cancer screening programme, diagnoses shot up 15 fold. Yet the death rate from thyroid cancer ...
TD Cowen 46th Annual Health Care Conference March 2, 2026 1:10 PM ESTCompany ParticipantsKave Niksefat - Senior Vice President of ...
TD Cowen 46th Annual Health Care Conference March 3, 2026 11:10 AM ESTCompany ParticipantsRoopal Thakkar - Executive VP of Research ...
The Hematologic Malignancies Market is projected to grow from USD 72,200.85 million in 2024 to USD 128,481.41 million by 2032, registering a CAGR of 7.47% during ...
About 60% of low‑risk prostate cancer patients are opting for active surveillance — and long‑term survival remains high.
Immunotherapy has been generally ineffective for prostate cancer because the tumors are considered immunologically "cold," meaning they do not attract enough immune cells to mount a strong attack.
For Patients With mCRPC, Results With Pluvicto in Real-World Settings Keep Pace With Clinical Trials
Real-world evidence shows Pluvicto matches pivotal trial benefits in PSMA-positive mCRPC, with longer PFS after an androgen receptor pathway inhibitor.
A meta-analysis seeks to determine if adding hormone therapy to radiotherapy after prostatectomy improves overall survival.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results